| Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin … TM Green, KH Young, C Visco, ZY Xu-Monette, A Orazi, RS Go, O Nielsen, ... American Society of Clinical Oncology (ASCO), 2012 | 804 | 2012 |
| MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression … S Hu, ZY Xu-Monette, A Tzankov, T Green, L Wu, A Balasubramanyam, ... Blood, The Journal of the American Society of Hematology 121 (20), 4021-4031, 2013 | 802 | 2013 |
| Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study F Passamonti, C Cattaneo, L Arcaini, R Bruna, M Cavo, F Merli, ... The Lancet Haematology 7 (10), e737-e745, 2020 | 545 | 2020 |
| The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation D Rossi, V Spina, C Deambrogi, S Rasi, L Laurenti, K Stamatopoulos, ... Blood, The Journal of the American Society of Hematology 117 (12), 3391-3401, 2011 | 422 | 2011 |
| Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large … C Visco, Y Li, ZY Xu-Monette, RN Miranda, TM Green, A Tzankov, W Wen, ... Leukemia 26 (9), 2103-2113, 2012 | 401 | 2012 |
| Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP … ZY Xu-Monette, L Wu, C Visco, YC Tai, A Tzankov, W Liu, ... Blood, The Journal of the American Society of Hematology 120 (19), 3986-3996, 2012 | 391 | 2012 |
| CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL … S Hu, ZY Xu-Monette, A Balasubramanyam, GC Manyam, C Visco, ... Blood, The Journal of the American Society of Hematology 121 (14), 2715-2724, 2013 | 279 | 2013 |
| Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia D Rossi, L Terzi-di-Bergamo, L De Paoli, M Cerri, G Ghilardi, A Chiarenza, ... Blood, The Journal of the American Society of Hematology 126 (16), 1921-1924, 2015 | 263 | 2015 |
| Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation C Visco, S Finotto, R Zambello, R Paolini, A Menin, R Zanotti, F Zaja, ... Journal of clinical oncology 31 (11), 1442-1449, 2013 | 236 | 2013 |
| Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International … C Visco, A Tzankov, ZY Xu-Monette, RN Miranda, YC Tai, Y Li, W Liu, ... Haematologica 98 (2), 255, 2013 | 195 | 2013 |
| Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection L Arcaini, C Besson, M Frigeni, H Fontaine, M Goldaniga, M Casato, ... Blood, The Journal of the American Society of Hematology 128 (21), 2527-2532, 2016 | 180 | 2016 |
| Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi L Arcaini, D Vallisa, S Rattotti, VV Ferretti, AJM Ferreri, P Bernuzzi, ... Annals of Oncology 25 (7), 1404-1410, 2014 | 173 | 2014 |
| Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP A Tzankov, ZY Xu-Monette, M Gerhard, C Visco, S Dirnhofer, N Gisin, ... Modern pathology 27 (7), 958-971, 2014 | 170 | 2014 |
| Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo … F Merli, S Luminari, F Ilariucci, M Petrini, C Visco, A Ambrosetti, ... British journal of haematology 156 (3), 346-353, 2012 | 159 | 2012 |
| Prevalence and Clinical Implications of Epstein–Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries CY Ok, L Li, ZY Xu-Monette, C Visco, A Tzankov, GC Manyam, ... Clinical Cancer Research 20 (9), 2338-2349, 2014 | 153 | 2014 |
| Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi C Visco, A Chiappella, L Nassi, C Patti, S Ferrero, D Barbero, ... The Lancet Haematology 4 (1), e15-e23, 2017 | 145 | 2017 |
| Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia C Visco, M Ruggeri, M Laura Evangelista, R Stasi, R Zanotti, I Giaretta, ... Blood, The Journal of the American Society of Hematology 111 (3), 1110-1116, 2008 | 143 | 2008 |
| Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL ZY Xu-Monette, M Xiao, Q Au, R Padmanabhan, B Xu, N Hoe, ... Cancer immunology research 7 (4), 644-657, 2019 | 129 | 2019 |
| Autoimmune cytopenias in chronic lymphocytic leukemia C Visco, W Barcellini, F Maura, A Neri, A Cortelezzi, F Rodeghiero American journal of hematology 89 (11), 1055-1062, 2014 | 129 | 2014 |
| Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma Q Ye, ZY Xu-Monette, A Tzankov, L Deng, X Wang, GC Manyam, C Visco, ... Oncotarget 7 (3), 2401, 2016 | 127 | 2016 |
